Palo Alto, Calif.- and Munich-based Middle Peak is developing technology to treat mitral valve disease with an implantable device designed to simulate the shape of the posterior leaflet to stop mitral regurgitation.
The round also included contributions from BioMedInvest II LP, Wellington Partners, Seventure Partners and High-Tech Gruenderfonds.
“We are delighted to have Biomed Partners and Edwards LifeSciences as additional investors. Their involvement further affirms our novel approach to treating mitral valve disease. These additional resources will further accelerate pre-clinical and clinical development,” Middle Peak co-founder & CEO Dr. Michael Lesh said in prepared remarks.
Middle Peak reported raising the 1st tranche of the Series A round in June.